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Severe emphysema patients who have been treated with endobronchial coils have been shown to initially
benefit, but slowly decline in the years thereafter. Re-treating a patient with endobronchial coils could
potentially lead to new improvements andmay again reduce the rate of further decline. To our knowledge,
until now, no results are published about patients who are re-treated. The primary aim of this study is to
investigate the safety and feasibility of re-treating severe emphysema patients with endobronchial coils,
using the PneumRx coil system. Furthermore, as secondary aim, we will evaluate the efficacy of re-treating
these patients. Patients who at least 2 years ago were treated with endobronchial coils and responded clin-
ically meaningful to this treatment were included in the study and re-treated. Safety was evaluated by the
number of reported adverse events. Efficacy was evaluated 6 months after re-treatment, and measured
by the change in quality of life, exercise capacity and pulmonary function testing. Eight patients were re-
treated at a median of 1382 days (range 849–1545) after initial coil treatment with a median additional of 12
(10–15) coils per patient. During treatment, and until 6 months of follow-up, no unexpected adverse events
occurred. Quality of life, exercise capacity and lung function did not change significantly 6 months after
re-treatment. The results of this pilot study suggest that re-treating patients with endobronchial coils is fea-
sible and safe. However, larger studies are needed to confirm these results and to investigate the efficacy
and thus the clinical relevance.
Introduction
In the past decade, the endobronchial coil treatment, a minor
invasive bronchoscopic lung volume reduction treatment option
for patients with severe emphysema was developed and investi-
gated (1–4). The endobronchial coil is designed to compress the
areas of lung parenchyma most damaged by emphysema. This
compression reduces airflow to the treated portions of the lung,
allowing enhanced airflow to healthier untreated portions of the
lung (5). This technique is an alternative for patients who do not
qualify for treatment with one-way endobronchial valves due
to the presence of collateral ventilation, or lung volume reduc-
tion surgery due to a homogeneous emphysema distribution or
comorbidities (6,7).
The combined data of four studies performed in Europe
investigating the endobronchial coil treatment showed statisti-
cally significant improvements in pulmonary function, exercise
capacity and quality of life at both 6 months and 12 months
post treatment (1). Furthermore, a recently published random-
ized controlled trial showed statistically significant differences
between the treatment group and control group 12 months post
treatment in exercise capacity, lung function and quality of life
parameters (2).
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Recently, we published the results of our single-center long-
term follow-up analysis, showing that the initial improvements
in pulmonary function, exercise capacity and quality of life are
slowly decreasing in the 2 years following the first treatmentwith
the endobronchial coil system (8). This decline could be caused
by natural decline due to ageing and disease progression, but
could also be caused by a diminishing effect of the treatment.
Re-treating the patient with endobronchial coils in other parts
of the lung could potentially lead to new improvements in lung
function, dyspnoea, exercise capacity and quality of life andmay
reduce the rate of decline.
To our knowledge, until now, no results are published about
patients who are re-treated with the endobronchial coil system.
Therefore, the aim of this study is to investigate the safety and
feasibility of re-treating patients with severe emphysema with
the endobronchial coil system. Furthermore, wewill evaluate the
efficacy of re-treating these patients.
Methods
Study population
Between April 2009 and September 2012, 49 patients were
treated with the endobronchial coil system at our hospital in
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1 of 3 pilot studies (NCT01220908 (9), NCT01328899 (10)
and NCT01421082 (11)). After completing these studies,
patients were invited for a yearly voluntary follow-up visit to
our hospital, and patients who indicated that they would like
additional treatment could participate in this ‘RECOIL’ trial
(NCT02012673). Patients could only be included in this trial
when the initial coil treatment was at least 24 months ago and
had a significant improvement in either 6-minute walk distance,
FEV1 or SGRQ score at 6 months after the initial treatment. The
complete list of inclusion and exclusion criteria can be found
in the online supplement (S1). The study was approved by the
ethics committee of the University Medical Center Groningen,
and all patients provided written informed consent.
Endobronchial coil treatment
Theperformed endobronchial coil treatment has been described
before in detail (5,9). Based on the position of the already placed
coils in the past and a new high-resolution chest CT (HRCT)
scan, the pulmonary physician decided at which location in the
lung, the additional coils were placed. The coils were placed by
bronchoscope in one procedure under general anaesthesia.
Study design andmeasurements
Patients were reviewed and tested in the outpatient clinics at
baseline and 6 months following the procedure. Safety was eval-
uated by reporting all adverse events until 6 months of follow-
up. The following measurements were performed at the two
visits. Pulmonary function was measured by spirometry and
body plethysmography (Jaeger MasterScreenTM, CareFusion,
Germany) according to the ATS/ERS guidelines (12,13). Exer-
cise capacity was measured by a 6-minute walk distance test
according to the ATS guidelines (14). Quality of life was mea-
sured by the St. George’s Respiratory Questionnaire (SGRQ)
(15) and Clinical COPD Questionnaire (CCQ) (16). Dyspnoea
severity wasmeasured by themodifiedMedical Research Coun-
cil scale (mMRC) score (17).
Statistical analyses
Safety will be evaluated descriptively. To evaluate the effi-
cacy of re-treating patients with the endobronchial coil sys-
tem, non-parametric statistics will be performed due to the low
number of patients. Descriptive statistics will be presented as
median (range). To compare the difference in efficacy param-
eters between baseline and 6-month follow-up, a Wilcoxon
signed-rank test will be performed. p-values below 0.05 are
considered statistically significant. Statistical analyses were per-
formed using IMB SPSS Statistics version 22.
Results
Study population and procedure characteristics
In total, 8 patients participated in this pilot study between
January 2014 and February 2016. Patient characteristics are
shown in Table 1. Procedure characteristics per patient are
shown in Table 2. Patients were re-treated after a median of
Table . Patient characteristics (n= ).
Female/Male, n /
Age, years . (–)
Pack-years, years . (–)
StO, %  (–)
PaCO, kpa . (.–.)
PaO, kpa . (.–.)
SGRQ symptoms, score . (.–.)
SGRQ activity, score . (.–.)
SGRQ impact, score . (.–.)
SGRQ total, score . (.–.)
CCQ total, score . (.–.)
mMRC, score  (–)
MWD, meter  (–)
FEV, %pred . (–)
FVC, %pred . (–)
RV, %pred  (–)
Data are presented as n(%) or median (range).
StO, Transcutaneous oxygen saturation measured at room air, PaCO:arterial par-
tial pressure of carbon dioxide; PaO, arterial partial pressure of oxygen; SGRQ,
St. George’s Respiratory Questionnaire; CCQ, Clinical COPDQuestionnaire; mMRC,
modiﬁed Medical Research Council scale; MWD, -minute walk distance; FEV,
Forced expiratory volume in -second; FVC, Forced Vital Capacity; RV, Residual
Volume.
1382 days (approximately 3 year and 10 months; range: 849–
1545 days) after the initial treatment. All treatments were exe-
cuted according to the treatment plan. The median procedure
timewas 24.5minutes (range 12–32), and themedian number of
coils placedwas 12 (range 10–15). Figure 1 shows the chest X-ray
of one example patient after the initial treatment and after the
re-treatment with coils. Median hospital stay was 1 night (range
1–4) after the procedure.
Safety
Table 3 shows the reported serious and non-serious adverse
events. During the study, no death, respiratory failure, pneu-
mothorax or severe haemoptysis occurred. Within the first
month after the treatment, 1 patient had a COPD exacerba-
tion that required hospitalization. Furthermore, 1 patient had a
coil associated opacity reaction, 1 patient experienced increased
dyspnoea and 2 patients chest pain (non-cardiac) resolving
with medication. Between 1-month and 6-month follow-up,
2 patients were hospitalized for a COPD exacerbation and 1
patient for a pneumonia. Furthermore, 1 patient had a COPD
exacerbation resolving with medication. None of the occurred
serious adverse events were deemed to be directly related to the
device or procedure.
Efficacy
No significant improvements were found 6 months after the
re-treatment in quality of life, exercise capacity or pulmonary
function parameters (all p > 0.05, Table 4). Figure 2 shows
the change in quality of life, exercise capacity and pulmonary
function before and after the initial treatment and after the re-
treatment with endobronchial coils. Individual patient data are
shown in Figure S2 in the online supplement.
Discussion
To our knowledge, until now, this is the first study that
publishes results of re-treating patients with endobronchial
COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 341
Table . Procedure characteristics per patient.
Patient Initial target Days after initial target Re-coil target Number of coils Procedure time (min) Hospital admission days
 RUL+ RLL  LUL+ LLL   
 LUL+ LLL+RUL  LLL   
 RUL+ LUL  LUL+ LLL   
 RUL+ RLL  LUL+ LLL   
 RUL+ LUL  LLL   
 RUL+ LUL  LLL   
 RUL+ LUL  RLL   
 RUL+ LUL  RLL   
RUL, Right upper lobe; RLL, Right lower lobe; LUL, Left upper lobe; LLL, Left lower lobe.
Figure . Chest X-ray of  example patient after the initial treatment and after the re-treatment with coils. Panel (a) Chest X-ray after initial treatment. Panel (b) Chest X-ray
after re-treatment with coils.
Figure . Change in quality of life, exercise capacity and lung function (n= ) Data are presented as mean and standard error of the mean (error-bars). The baseline of the
RECOIL study was  days (range – days) after the initial treatment.
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Table . Number of reported (serious) adverse events.
< days Between  and  days
Serious adverse events after treatment after treatment
Death  








Coil associated opacity reaction  
Dyspnea  
Inﬂuenza  
COPD exacerbation  
Chest pain  
Data are presented as number of adverse events reported.
coils. Our results show that it is feasible to re-treat patients
with endobronchial coils system approximately 3 years after
the initial treatment. Furthermore, even in this very diseased
patient group, no unexpected serious or non-serious adverse
events occurred within 6 months after treatment. In this small
group, no significant changes in efficacy parameters were found
6 months after the treatment.
Our results suggest that it is feasible to re-treat patients with
the endobronchial coils system approximately 3 years after the
initial treatment. All individual treatment plans based on the
HRCT scan and previous treatment with the endobronchial coil
system were executed without problems. However, it should be
further investigated how the additional coil treatment procedure
can be optimized. For example, we choose to include patients
who were treated with coils at least 2 years ago. Our longitudinal
pilot study showed that the treatment with coils was beneficial
for a large group of patients after 1 year, with after 3-year overall
clinical parameters returning to baseline (8). It is questionable
whether it is better to add coils earlier when the decline starts or
later when the benefit is diminished completely. Furthermore,
in this study, a total of 10–15 additional coils were placed in 1
procedure. In the initial treatment, 6 patients who were treated
bilaterally received 19–24 coils in 2 lungs and 2 patients who
were treated unilaterally received 15 coils in 1 lung. Perhaps, it
can be speculated that the number of additional coils placed was
not sufficient to obtain optimal clinical benefit.
During hospitalization, between hospitalization and 1 and
6 months after treatment, no unexpected adverse events
Table . Changes in eﬃcacy parameters  months after treatment (n= ).
Baseline Re-Coil  Months FU p-value
SGRQ, total score . . .
CCQ, total score . . .
mMRC, score . . .
MWD, meter   .
FEV, liter . . .
FVC, liter . . .
RV, liter . . .
Data are presented asmedian. Diﬀerencebetweenbaseline andmonths follow-up
was analyzed with a Wilxocon signed rank test.
FU, Follow-up; SGRQ, St. George’s Respiratory Questionnaire; CCQ, Clinical COPD
Questionnaire;mMRC,modiﬁedMedical Research Council scale; MWD, -minute
walk distance; FEV, Forced expiratory volume in -second; FVC, Forced Vital
Capacity; RV, Residual Volume.
occurred. These results suggest that it is safe to re-treat patients
with the endobronchial coils system. However, the limited num-
ber of patients precludes drawing firm conclusions regarding
safety of re-treatment. The type of adverse events were compa-
rable with other trials investigating the endobronchial coil treat-
ment (1,2). Furthermore, the frequency of the occurrence of the
adverse events in this trial was lower compared to the other tri-
als, but also the sample size was lower and the trial was only per-
formed at 1 hospital.
We found earlier that the rate of decline in these patients in
terms of FEV1 did not change after the treatment with endo-
bronchial coils (8), which was also found after lung volume
reduction surgery (LVRS) (18,19). Emphysema is character-
ized by gradual destruction and disappearance of alveolar walls,
which probably also continue after the treatment with coils. The
coil is designed to compress the areas of lung parenchyma most
damaged by emphysema, and placing additional coils could tar-
get the lung parenchyma areas, which show on-going destruc-
tion. In this pilot study, the additional coils were placed in a dif-
ferent target lobe than the initial treatment, while it also would
be interesting to investigate whether treatment in the same tar-
get lobe is feasible and effective. However, with already coils
being present in all subsegments of the already treated lobes, this
might be challenging.
Re-treating patients with endobronchial coils is only clini-
cal relevant when patients benefit from this additional treat-
ment. The subjects included in this pilot study responded before
to the coil treatment and had an initial residual volume of
255% of predicted and were therefore likely to benefit from
re-treatment (2). However, our results showed no significant
improvement in quality of life, dyspnoea severity, exercise capac-
ity and lung function 6 months after the re-treatment. On the
other hand, also noworsening of these parameters was observed
after the re-treatment with endobronchial coils. However, the
number of patients in this trial is too low to draw definitive
conclusions about efficacy; thus, a larger trial is needed to
investigate whether patients will benefit from re-treatment with
endobronchial coils or not. Unfortunately, there are only lim-
ited alternative treatment options for this group of patients.
The patients in this trial could not be treated with endo-
bronchial valves because of the presence of collateral ventilation
and due to the main homogeneous distribution of the emphy-
sema, LVRS was neither an option (20). Lung transplantation
could be an option, but this treatment is only available for a
very selective group of severe emphysema patients with limited
co-morbidity.
The main disadvantage of this study was the low number
of patients. The main aim of this pilot study was to investigate
whether it is feasible and safe to re-treat patients with endo-
bronchial coils more than 2 years after the initial treatment.
The results suggest that re-treating is feasible and safe but a
larger multicentre study is necessary to confirm these results.
Furthermore, our patients were one of the first ones ever treated
with endobronchial coils in pilot studies, whichmay have biased
the results.
In conclusion, the results of this pilot study suggest that it
is feasible and safe to re-treat patients with endobronchial coils
approximately 3 years after the initial coil treatment. In this
small group of patients, little or no benefit was found of the
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re-treatment with coils. However, larger studies are needed to
confirm these results and to investigate the efficacy and thus the
clinical relevance of re-treating patients.
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